Tag Archives: HDV

December, 2018

17 December
FDA Grants Breakthrough Therapy Designation to Eiger’s Lonafarnib for Treatment of Hepatitis Delta Virus Infection

PALO ALTO, Calif., Dec. 17, 2018 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for lonafarnib for the treatment of hepatitis delta virus …
Share

22 April
Eiger Biopharma Licenses an Investigational HVD Therapy from BMS

PALO ALTO, Calif., April 20, 2016 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) announced today that it has licensed Pegylated Interferon Lambda-1a (“Lambda”), a novel, well-characterized, first in class Type III interferon to be studied as an investigational therapy for hepatitis delta virus (HDV) infection, from Bristol-Myers Squibb. Lambda has …
Share